ES2902456T3 - Composiciones farmacéuticas que comprenden agentes antibacterianos - Google Patents

Composiciones farmacéuticas que comprenden agentes antibacterianos Download PDF

Info

Publication number
ES2902456T3
ES2902456T3 ES14806074T ES14806074T ES2902456T3 ES 2902456 T3 ES2902456 T3 ES 2902456T3 ES 14806074 T ES14806074 T ES 14806074T ES 14806074 T ES14806074 T ES 14806074T ES 2902456 T3 ES2902456 T3 ES 2902456T3
Authority
ES
Spain
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
formula
cefepime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14806074T
Other languages
English (en)
Spanish (es)
Inventor
Sachin Bhagwat
Mahesh Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wockhardt Ltd
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Application granted granted Critical
Publication of ES2902456T3 publication Critical patent/ES2902456T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
ES14806074T 2013-10-22 2014-10-22 Composiciones farmacéuticas que comprenden agentes antibacterianos Active ES2902456T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2014/065522 WO2015059643A1 (en) 2013-10-22 2014-10-22 Pharmaceutical compositions comprising antibacterial agents
IN3309MU2013 IN2013MU03309A (enExample) 2013-10-22 2014-10-22

Publications (1)

Publication Number Publication Date
ES2902456T3 true ES2902456T3 (es) 2022-03-28

Family

ID=52003012

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14806074T Active ES2902456T3 (es) 2013-10-22 2014-10-22 Composiciones farmacéuticas que comprenden agentes antibacterianos

Country Status (18)

Country Link
US (1) US9827235B2 (enExample)
EP (1) EP3060213B1 (enExample)
JP (2) JP2016538258A (enExample)
KR (1) KR102340010B1 (enExample)
CN (2) CN106102741A (enExample)
AU (1) AU2014338612C1 (enExample)
BR (1) BR112016008979B1 (enExample)
CA (1) CA2928364C (enExample)
DK (1) DK3060213T3 (enExample)
ES (1) ES2902456T3 (enExample)
HU (1) HUE057504T2 (enExample)
IN (1) IN2013MU03309A (enExample)
MX (1) MX375934B (enExample)
NZ (1) NZ719215A (enExample)
PL (1) PL3060213T3 (enExample)
PT (1) PT3060213T (enExample)
RU (1) RU2702361C2 (enExample)
WO (1) WO2015059643A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107580595B (zh) * 2015-05-07 2020-09-18 拜欧蒂姆公司 杂环化合物及它们在预防或治疗细菌感染中的应用
CN109310682A (zh) * 2016-06-17 2019-02-05 沃克哈特有限公司 抗菌组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465428B1 (en) * 1999-08-27 2002-10-15 Aventis Pharma S.A. Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime
MX2007007235A (es) * 2004-12-17 2007-10-19 Venus Remedies Ltd Combinacion de antibioticos para proporcionar una solucion total al tratamiento de infecciones.
RU2366450C1 (ru) * 2008-08-04 2009-09-10 Валентина Васильевна Малиновская Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций
CA2842777C (en) * 2011-07-26 2015-12-29 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
BR112013028813B1 (pt) * 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
HUE046893T2 (hu) * 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
AU2014206087A1 (en) * 2013-01-14 2015-05-28 Wockhardt Limited Compositions and methods for treating bacterial infections

Also Published As

Publication number Publication date
CN113577084A (zh) 2021-11-02
IN2013MU03309A (enExample) 2015-07-17
AU2014338612B2 (en) 2019-12-19
PL3060213T3 (pl) 2022-02-14
US20160303104A1 (en) 2016-10-20
KR20160072254A (ko) 2016-06-22
DK3060213T3 (da) 2022-01-03
WO2015059643A1 (en) 2015-04-30
RU2016115376A (ru) 2017-11-28
NZ719215A (en) 2020-04-24
KR102340010B1 (ko) 2021-12-16
PT3060213T (pt) 2021-12-24
CA2928364A1 (en) 2015-04-30
MX375934B (es) 2025-03-07
RU2702361C2 (ru) 2019-10-08
CA2928364C (en) 2021-11-23
CN106102741A (zh) 2016-11-09
AU2014338612C1 (en) 2020-09-24
RU2016115376A3 (enExample) 2018-07-02
US9827235B2 (en) 2017-11-28
JP2019116508A (ja) 2019-07-18
HUE057504T2 (hu) 2022-05-28
BR112016008979A2 (enExample) 2017-08-01
MX2016005161A (es) 2016-10-05
EP3060213A1 (en) 2016-08-31
JP2016538258A (ja) 2016-12-08
BR112016008979B1 (pt) 2023-04-25
EP3060213B1 (en) 2021-10-13
JP6886996B2 (ja) 2021-06-16

Similar Documents

Publication Publication Date Title
WO2016151543A1 (en) Pharmaceutical compositions comprising antibacterial agents
US9789097B2 (en) Pharmaceutical compositions comprising antibacterial agents
AU2014338612B2 (en) Pharmaceutical compositions comprising antibacterial agents
CA2931070A1 (en) Antibacterial compositions
CN106029068A (zh) 包含抗菌剂的药物组合
US20170000775A1 (en) Pharmaceutical compositions comprising antibacterial agents
AU2014338612A1 (en) Pharmaceutical compositions comprising antibacterial agents
CN106163519A (zh) 包含抗菌剂的药物组合物
KR20160138304A (ko) 항균 물질들을 포함하는 약학 조성물
ES2804500T3 (es) Composiciones farmacéuticas que comprenden agentes antibacterianos
EP3125887A1 (en) Pharmaceutical compositions comprising cefepime or sulbactam
WO2018193368A1 (en) Antibacterial compositions
BR112017003444B1 (pt) Composições farmacêuticas compreendendo ertapenem e um composto de fórmula (i)
KR20160072262A (ko) 항균제를 포함하는 제약학적 조성물